Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Z. Potter

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
New era for novel CNS drug developmentWilliam Z Potter
Expert Review of Clinical Pharmacology|December 25, 2014
Optimizing early Go/No Go decisions in CNS drug developmentWilliam Z Potter
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 14, 2023
Real changes can enhance information yield on novel psychopharmacologic agentsWilliam Z Potter
Advances in Neurobiology|November 19, 2024
Public-Private Partnerships for Neuropsychiatric Drug Development: A PerspectiveWilliam Z Potter
Journal of Clinical Psychopharmacology|October 17, 2022
Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding MechanismsWilliam Z Potter
The Journal of Clinical Investigation|August 28, 2012
Mining the secrets of the CSF: developing biomarkers of neurodegenerationWilliam Z Potter
Journal of Clinical Psychopharmacology|April 30, 2022
Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human TrialsMargaret C Grabb, William Z Potter
Convulsive Therapy|January 1, 1985
Clinical "Response" to "Convulsive" TherapyMatthew V. Rudorfer, William Z. Potter
Annual Review of Pharmacology and Toxicology|April 12, 2005
Biomarkers in psychotropic drug development: integration of data across multiple domainsPeter R Bieck, William Z Potter
Expert Opinion on Drug Discovery|December 7, 2013
Public-private partnerships to revitalize psychiatric drug discoveryLinda S Brady, William Z Potter
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
New era for novel CNS drug developmentWilliam Z Potter
Expert Review of Clinical Pharmacology|December 25, 2014
Optimizing early Go/No Go decisions in CNS drug developmentWilliam Z Potter
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 14, 2023
Real changes can enhance information yield on novel psychopharmacologic agentsWilliam Z Potter
Advances in Neurobiology|November 19, 2024
Public-Private Partnerships for Neuropsychiatric Drug Development: A PerspectiveWilliam Z Potter
Journal of Clinical Psychopharmacology|October 17, 2022
Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding MechanismsWilliam Z Potter
The Journal of Clinical Investigation|August 28, 2012
Mining the secrets of the CSF: developing biomarkers of neurodegenerationWilliam Z Potter
Journal of Clinical Psychopharmacology|April 30, 2022
Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human TrialsMargaret C Grabb, William Z Potter
Convulsive Therapy|January 1, 1985
Clinical "Response" to "Convulsive" TherapyMatthew V. Rudorfer, William Z. Potter
Annual Review of Pharmacology and Toxicology|April 12, 2005
Biomarkers in psychotropic drug development: integration of data across multiple domainsPeter R Bieck, William Z Potter
Expert Opinion on Drug Discovery|December 7, 2013
Public-private partnerships to revitalize psychiatric drug discoveryLinda S Brady, William Z Potter
Pageof 9